Lifesci Capital upgraded shares of DBV Technologies (NASDAQ:DBVT - Free Report) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.
A number of other equities research analysts have also issued reports on the company. The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research note on Thursday, May 29th. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. HC Wainwright upped their price objective on DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 5th. Finally, JMP Securities restated a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a report on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $14.75.
Read Our Latest Report on DBVT
DBV Technologies Trading Up 3.2%
Shares of NASDAQ:DBVT traded up $0.28 during trading on Thursday, hitting $9.16. 10,445 shares of the stock were exchanged, compared to its average volume of 190,661. The company has a fifty day moving average price of $9.25 and a two-hundred day moving average price of $6.36. The company has a market cap of $250.89 million, a PE ratio of -1.86 and a beta of -0.63. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $12.78.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. Equities research analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.
Institutional Trading of DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
